Caring for Older Adults with Acute Myeloid Leukemia: Best Practices for Aligning Patient Fitness and Preference with Available Therapies.

Five-year survival for adults over the age of 75 years is profoundly low, below 10%.

For many patients, current therapies fail to dramatically extend life or improve the quality of life.

These stark realities must inform clinical decision making and fuel further research.

This review critically examines current treatment options including recently approved targeted agents in the upfront and relapsed setting including FLT3 inhibitors, isocitrate dehydrogenase 1/2 inhibitors, and the newly approved menin inhibitors.